NYSE · ABBV
ABBVIE Inc.
$259.36 +$2.44 (+0.95%) 1D After hours
Session Pulse
Overnight session
chatter is
louder than usual
1
mentions on Sat
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
6/11
this week
Full pulse →
Key Metrics
$453.92B
Market cap
124.88×
P/E · TTM
$62.82B
Revenue · TTM
$3.64B
Net income
EPS · TTM
$2.05
Dividend yield
2.6%
Free cash flow
$19.98B
Beta · 1Y
-0.04
EBITDA · TTM
$6.74B
Gross margin
—
Snapshot
Market cap$453.92B
Enterprise value$517.12B
Shares outstanding1.8B
52-wk range$187.62 – $261.64
Avg volume · 20D6.3M
Net cash
−$63.20B
Book value / share$-3.76
IndustryPharmaceutical Preparations
ExchangeNYSE
About ABBVIE Inc.
IPO dateDec 10, 2012
Employees57000
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E124.88
P/S7.23
P/FCF22.72
EV/EBITDA76.68
EV/Sales8.23
Graham №—
Profitability
Gross
—
Operating
9.5%
Net
5.8%
FCF
31.8%
ROE / ROIC
-218.3% · 6.4%
Financial Health
Current ratio0.80
Quick ratio0.68
Debt / equity-10.95
Debt / EBITDA
10.80
Net cash
−$63.20B
Working capital−$8.57B
Cash Flow · TTM
Operating CF
$21.22B
Capex
−$1.24B
Free cash flow
$19.98B
Buybacks
$1.51B
Dividends paid
$11.82B
Shareholder yield
2.9%
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings